<DOC>
	<DOCNO>NCT00243087</DOCNO>
	<brief_summary>RATIONALE : BI 2536 may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose BI 2536 treat patient refractory relapse advance non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Investigation Safety , Tolerability Maximum Tolerated Dose ( MTD ) BI 2536 Patients With Recurrent Advanced Aggressive Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose BI 2536 patient refractory relapse advanced aggressive non-Hodgkin 's lymphoma . - Determine safety tolerability drug patient . Secondary - Determine pharmacokinetic profile drug patient . - Determine , preliminarily , antitumor activity drug patient . OUTLINE : This dose-escalation , open-label , uncontrolled , multicenter study . Patients receive BI 2536 IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BI 2536 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity first treatment course . Up 24 patient treated MTD . After completion study treatment , patient follow periodically disease progression initiation another cancer treatment . PROJECTED ACCRUAL : A maximum 50 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced aggressive nonHodgkin 's lymphoma ( NHL ) , include follow subtypes : Bcell NHL , include follow subtypes : Diffuse large Bcell lymphoma Primary mediastinal ( thymic ) Bcell lymphoma Intravascular large Bcell lymphoma Immunoblastic Bcell lymphoma Mantle cell lymphoma Burkitt 's lymphoma Follicular grade 3b lymphoma Tcell NHL , include follow subtypes : Anaplastic large cell lymphoma Peripheral Tcell lymphoma , otherwise specify De novo transform disease Refractory ( i.e. , disease amenable standard therapy ) relapse disease , evidence 1 following : Refractory OR relapse ≥ 1 prior combination chemotherapy regimen Refractory OR relapse prior CD20based immunotherapy ( patient eligible receive therapy ) Refractory prior highdose chemotherapy autologous stem cell transplantation AND ≥ 100 day post transplantation At least 1 bidimensionally measurable lesion ≥ 1.5 cm CT scan , MRI , xray , clinical examination No active CNS lymphoma PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 9 g/dL No known coagulopathy Hepatic ALT and/or AST ≤ 2.5 time upper limit normal ( ULN ) ( &lt; 5 time ULN due hepatic lymphoma ) Bilirubin ≤ 1.5 time ULN Renal Creatinine ≤ 2.0 mg/dL Immunologic No known HIV infection No serious active infection require IV antibiotic antifungal antiviral agent Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception 1 year completion study treatment No known suspect alcohol drug abuse No sensory motor neuropathy ≥ grade 3 No malignancy within past 5 year except nonmelanoma skin cancer No lifethreatening illness organ dysfunction would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics See Radiotherapy More 3 week since prior concurrent immunotherapy No prior allogeneic bone marrow transplantation Chemotherapy See Disease Characteristics More 3 week since prior concurrent chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy No concurrent hormonal therapy Radiotherapy No prior radiotherapy site measurable disease unless documented disease progression completion radiotherapy More 8 week since prior concurrent systemic radioimmunotherapy More 3 week since prior concurrent radiotherapy Concurrent palliative radiotherapy sit measurable target lesion allow symptom control provide reason radiotherapy reflect progressive disease Other No concurrent warfarin therapeutic anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
</DOC>